The acquisition strengthens Nestlé Health Science’s capacity to deliver personalised healthcare to address chronic medical conditions through nutrition, especially in the areas of metabolic health and brain health, the company said.
Luis Cantarell, Nestlé Health Science president and CEO, said: “The acquisition of the Pamlab business is aligned with our strategic ambition to provide science-based nutritional solutions for people with chronic medical conditions. Pamlab will particularly strengthen our brain health platform and provide us an additional foothold in metabolic health in the US.
“By leveraging our nutrition heritage and US operations with Pamlab’s proven expertise in medical foods and strong sales force capabilities, together we can play a key role in helping to manage certain chronic diseases and improve the quality of patients’ lives.”
Source: Nestlé
© FoodBev Media Ltd 2024